for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BioNTech SE - ADR

22UAy.F

Latest Trade

73.08EUR

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

14.80

 - 

102.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
73.08
Open
--
Volume
--
3M AVG Volume
68.04
Today's High
--
Today's Low
--
52 Week High
102.00
52 Week Low
14.80
Shares Out (MIL)
232.67
Market Cap (MIL)
22,471.67
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Pfizer Says Phase 2/3 Trial Of COVID-19 Vaccine Has Enrolled 39,862 Participants

Biontech And Pfizer Initiate Rolling Submission To European Medicines Agency

Biontech Says Request For COVID-19 Vaccine Approval Could Be Filed End Of Oct.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About BioNTech SE - ADR

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Industry

Biotechnology & Drugs

Contact Info

An der Goldgrube 12

55131

Germany

+49.6131.90840

https://biontech.de/

Key Stats

2.33 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2019

0.1K

2020(E)

0.4K
EPS (EUR)

2019

-0.850

2020(E)

-0.358
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
30.85
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
17.72
LT Debt To Equity (MRQ)
11.68
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Germany readies for coronavirus vaccine before end of year - Bild

Germany is making preparations to start vaccinations against the coronavirus before the end of the year, Bild daily reported on Friday.

Pfizer, J&J urge clarity from FDA on future of COVID-19 vaccine trials once a vaccine is available

Pfizer Inc <PFE.N> and Johnson & Johnson <JNJ.N> are seeking input from a U.S. Food and Drug Administration advisory committee on retaining and attracting volunteers for COVID-19 vaccine trials after a vaccine becomes available, if they know they might receive a placebo.

Britain partners with Oxford firm to assess coronavirus vaccine T cell responses

Britain on Thursday said it would partner with an Oxford-based firm to provide testing for the T cell response of coronavirus vaccine candidates to try to assess their immune responses.

Ecuador signs COVID-19 vaccine supply deals with pharma companies

Ecuador has signed supply agreements with major pharmaceutical firms including Pfizer Inc and BioNTech to provide millions of COVID-19 vaccines, the health minister said on Wednesday, adding it is seeking talks with Chinese laboratories for more supplies.

Pfizer, BioNTech start combined trials of COVID-19 vaccine candidate in Japan

Pfizer Inc <PFE.N> and BioNTech SE announced on Tuesday the start in Japan of combined Phase I and Phase II clinical trials of their mRNA vaccine candidate against the coronavirus.

Dow advances, S&P ekes out gain as vaccine timeline comes into focus

The S&P 500 posted a nominal gain on Friday as further clarity regarding the timeline for the development of a coronavirus vaccine and much better-than-expected retail sales data brought buyers back to the market.

Pfizer vaccine hopes lift world stocks; dollar, gold on the defensive

Global shares bounced on Friday while safe havens such as the dollar were on the defensive as investors welcomed news that drugmaker Pfizer Inc <PFE.N> could have a coronavirus vaccine ready in the United States by the end of this year.

Explainer: When will COVID-19 vaccines be generally available in the United States?

U.S. President Donald Trump and the head of the Centers for Disease Control and Prevention (CDC) have disagreed about when a COVID-19 vaccine would become widely available. Trump has said enough vaccine would be available for every American by April, while the CDC director...

Pfizer says earliest U.S. filing for COVID-19 vaccine would be late November

Pfizer Inc <PFE.N> said on Friday it could file in late November for U.S. authorization of the COVID-19 vaccine it is developing, suggesting that a vaccine could potentially be available in the United States by the end of the year.

US STOCKS-S&P 500, Dow close higher on vaccine update, retail sales beat

The S&P 500 advanced on Friday as further clarity regarding the timeline for the development of a coronavirus vaccine and much better-than-expected retail sales data and brought buyers back to the market.

EMERGING MARKETS-Latam FX up on vaccine optimism, Chile's peso breaks 4-day losing streak

* Chilean peso up after central bank leaves rates unchanged * Argentina central bank lowers Leliq rate to 36% * Mexican peso outperforms Latam peers for the week (Updates prices throughout) By Shreyashi Sanyal Oct 16 (Reuters) - Latin American currencies rose on Friday after...

GLOBAL MARKETS-Pfizer vaccine hopes lift world stocks; dollar, gold on the defensive

Global shares rose on Friday while safe-havens such as the dollar softened as investors welcomed news that drugmaker Pfizer Inc could have a coronavirus vaccine ready in the United States by the end of this year.

US STOCKS-Wall Street gains on vaccine news, retail sales surprise

* Indexes up: Dow 0.87%, S&P 0.55%, Nasdaq 0.35% (Updates to late afternoon, changes dateline, byline)

US STOCKS-Wall St inches higher on Pfizer vaccine update, upbeat consumer data

* Indexes up: Dow 0.7%, S&P 0.4%, Nasdaq 0.1% (Updates to early afternoon)

FTSE 100 snaps four-day losing streak on vaccine hopes

The FTSE 100 snapped a four-day losing streak on Friday after an upbeat coronavirus vaccine update from Pfizer and signs Brexit talks might continue until the year end for a possible trade deal with the European Union.

Vaccine hopes, upbeat earnings power European shares

European shares bounced on Friday on hopes that a vaccine for the novel coronavirus could be available in the United States before the end of the year, with a clutch of upbeat quarterly earnings also lifting sentiment after a torrid week.

US STOCKS-Wall Street climbs on vaccine hopes, upbeat consumer data

* Indexes up: Dow 0.90%, S&P 0.53%, Nasdaq 0.24% (Adds details; Updates prices)

EMERGING MARKETS-Latam FX rises on vaccine hopes, Chile's peso bucks 4-day losing streak

* Chilean peso up after central bank leaves rates unchanged * Argentina central bank lowers Leliq rate to 36% * Mexican peso outperforms Latam peers for the week By Shreyashi Sanyal Oct 16 (Reuters) - Latin American currencies rose on Friday after Pfizer said it could apply...

Q&A: Where are we in the COVID-19 vaccine race?

Drugmakers and research centers around the world are working on COVID-19 vaccines, with large global trials of several of the candidates involving tens of thousands of participants well underway.

US STOCKS-Wall St climbs on vaccine hopes, upbeat retail sales data

* Boeing up on report 737 MAX declared safe by Europe regulator

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up